Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B-cell lymphoma. [PDF]
Ma WL +11 more
europepmc +1 more source
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
Association Between Oral Cavity Cancer and Lymphoma: A Bidirectional Mendelian Randomization Analysis. [PDF]
Deng Y, Kang M.
europepmc +1 more source
Double Trouble: Renal Collision Tumors with Unexpected Histology-A Case Report with Review of Literature. [PDF]
Medapati P +3 more
europepmc +1 more source
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo +17 more
wiley +1 more source
Ovarian Lymphoma and Bone Metastasis Presenting With Paraparesis in an Adolescent: A Case Report. [PDF]
Darajatun RH, Aditiyono A, Salima S.
europepmc +1 more source
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Case Report: Non-traumatic splenic rupture as the first presentation of diffuse large B-cell lymphoma complicated by clinically diagnosed pulmonary aspergillosis supported by metagenomic next-generation sequencing. [PDF]
Zhao Y, Duan J.
europepmc +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Diffuse large B-cell lymphoma mimicking musculoskeletal nontuberculous mycobacterial infection: A fatal diagnostic challenge. [PDF]
Kim S, Lee SJ.
europepmc +1 more source

